Molecular imaging of cardiovascular disease using ultrasound

被引:0
作者
Flordeliza S. Villanueva
机构
[1] University of Pittsburgh Medical Center,Center for Ultrasound Molecular Imaging and Therapeutics, Cardiovascular Institute
[2] A351 Presbyterian University Hospital,undefined
来源
Journal of Nuclear Cardiology | 2008年 / 15卷
关键词
Nuclear Cardiology; Molecular Imaging; Ultrasound Contrast Agent; Myocardial Contrast Echocardiography; Leukocyte Adhesion Molecule;
D O I
暂无
中图分类号
学科分类号
摘要
Molecular imaging using probes that specifically home to function- or disease-specific targets is a promising tool for both basic research investigations as well as clinical diagnostics. Ultrasound-based molecular imaging utilizes acoustically active particles (contrast agents) bearing targeting ligands that specifically bind to a molecule of interest. In the presence of an ultrasound field, the bound particles are detectable as a persistent contrast effect during ultrasound imaging. Different types of targeted contrast agents have been reported, most of which share in common the presence of a gas encapsulated by a shell of varying chemical formulation. These agents, or “microbubbles,” are typically 2 to 4 µm in diameter, and have a natural resonance frequency that corresponds to the frequencies used in diagnostic echocardiography. This attribute makes it possible to induce microbubble resonance and non-linear oscillation at diagnostic ultrasound frequencies, leading to acoustic emissions from the microbubbles that can be detected as specific signals during two dimensional ultrasound imaging. Targeting ligands that have been attached to microbubbles include monoclonal antibodies, peptides, and the naturally occurring ligands for the receptor of interest, such as vascular endothelial growth factor. Because the contrast agents stay within the intravascular space, they are ideally suited for detection of endothelial epitopes, such as leukocyte adhesion molecules or angiogenesis receptors. Ultrasound molecular imaging with targeted contrast agents has been used to detect inflammation association with ischemia/reperfusion (ischemic memory), cardiac transplant rejection, early atherosclerosis, and angiogenesis. Application to tumor angiogenesis has also been reported using peptides that specifically bind to angiogenic tumor endothelium. Translation of ultrasound molecular imaging to the clinical arena will require optimization of contrast agent design to maximize specific binding, and customization of imaging systems to sensitively detect the binding events
引用
收藏
相关论文
共 265 条
  • [1] Skyba DM(1996)Hemodynamic characteristics, myocardial kinetics and microvascular rheology of FS-069, a second generation echocardiographic contrast agent capable of producing myocardial opacification from a venous injection J Am Coll Cardiol 28 1292-300
  • [2] Camarano G(2001)Improving ultrasound reflectivity and stability of echogenic liposomal dispersions for use as targeted ultrasound contrast agents J Pharm Sci 90 1917-26
  • [3] Goodman NC(1999)In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement J Am Coll Cardiol 33 867-75
  • [4] Price RJ(2000)Molecular imaging of stretch-induced tissue factor expression in carotid arteries with intravascular ultrasound Invest Radiol 35 227-34
  • [5] Skalak TC(2007)AI-700 pharmacokinetics, tissue distribution and exhaled elimination kinetics in rats Int J Pharm 328 35-41
  • [6] Kaul S(2001)Detection of coronary artery stenosis using power Doppler imaging Circulation 103 2624-30
  • [7] Huang S(2006)Deformable gas- filled microbubbles targeted to P-selectin J Control Release 114 288-99
  • [8] Hamilton AJ(2002)Myocardial and microcirculatory kinetics of BR14, a novel third-generation intravenous ultrasound contrast agent J Am Coll Cardiol 39 530-7
  • [9] Nagaraj A(2002)Microvascular rheology of Definity microbubbles after intra-arterial and intravenous administration J Am Soc Echocardiogr 15 396-403
  • [10] Tiukinhoy SD(2004)Intravascular ultrasound molecular imaging of atheroma components in vivo J Am Coll Cardiol 43 453-60